Lycia Therapeutics (LYCA) IPO deck
Lycia Therapeutics is a clinical-stage biotechnology company leveraging its LYTAC platform to degrade disease-causing extracellular proteins across autoimmune, inflammatory, and allergic diseases.
Lycia Therapeutics is a clinical-stage biotechnology company leveraging its LYTAC platform to degrade disease-causing extracellular proteins across autoimmune, inflammatory, and allergic diseases.
%20IPO%20deck){kind=link}